Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results
Reported Positive Data from Phase 2b Clinical Trial of Topical Ocular Reproxalap in Dry Eye Disease Announced Positive Top-Line Data from Investigator-Sponsored Phase 1/2 Clinical Trial of ADX-1612 in Malignant Mesothelioma Raised $67.6 Million, Operations Expected to be Funded Through 2020
View HTML
Toggle Summary Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference
LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C.
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2018 Financial Results
LEXINGTON, Mass. , Nov. 5, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Wednesday, November 14,
View HTML
Toggle Summary Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C.
View HTML
Toggle Summary Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock
LEXINGTON, Mass. , Sept. 27, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwritten public
View HTML
Toggle Summary Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass. , Sept. 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it intends to offer and sell,
View HTML
Toggle Summary Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial
Statistically Significant Improvement Across Multiple Symptom and Sign Measures Early Onset and Broad Range of Activity Supports Differentiated Product Profile Pivotal Clinical Testing Expected to Begin in 2019 Following Discussion with Regulatory Authorities LEXINGTON, Mass. , Sept.
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Phase 2b Dry Eye Disease Clinical Trial
LEXINGTON, Mass. , Sept. 25, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced it will hold a webcast and conference
View HTML
Toggle Summary Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer
61% Partial Response Rate of ADX-1612 in Combination with Platinum Therapy LEXINGTON, Mass. , Sept. 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Aldeyra) (NASDAQ: ALDX), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with
View HTML
Toggle Summary Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Phase 2b Results for Topical Ocular Reproxalap in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter 2018 Clinical Results from Investigator-Sponsored Trial of ADX-1612 in Mesothelioma Expected to be Released at the International Association for the Study of Lung Cancer
View HTML